Abstract: Methods of producing a protein capable of binding to a predetermined antigen, screening libraries containing such proteins, and proteins and synthetic genes containing randomized sequences are disclosed.

Abstract: High affinity species specific monoclonal antibodies are provided. The antibodies are anti-immunoglobulin antibodies which bind the Ig of a particular species but does not cross react with the Ig of another species. Methods for making and using the antibodies of the invention are provided.

Abstract: The instant invention provides novel molecules derived from the components of proinsulin using recombinant DNA technology. The invention provides molecules of the formula A--C--B wherein A is the A-chain of an insulin species, B is the B-chain of an insulin species and C is a connecting peptide. These molecules possess insulin-like activity and are useful for the treatment of diabetes mellitus, particularly non-insulin dependent diabetes mellitus. These molecules are also useful for the production of insulin and constitute a novel pathway for the recombinant production of insulin species. The invention provides a method of making insulin proceeding through the compounds of the invention as intermediates. The instant invention further provides recombinant DNA compounds which encode the compounds of the invention.

Abstract: The present invention resides, in part, in cloned DNA fragments encoding a histidine-rich protein of Plasmodium falciparum (PfHRP-II). PfHRP-II is a malarial antigen that is secreted by the parasite into erythrocytes. The protein is characterized by tandem repeats of high histidine, alanine and aspartate content. The protein is found to have high affinity for divalent cations. Cloning and characterization of the PfHRP-II gene are described, as are antibodies against PfHRP-II.

Abstract: A homogenous sample of identical bispecific antibody determinants, each determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being specific for a different antigenic determinant and including at least the F(ab') portion of a monoclonal IgG antibody. The bispecific antibody determinants are useful, e.g., in the formation of multilamellar assemblies and in enzymatic assays.

Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.

Abstract: The subject invention relates to monoclonal antibodies and uses thereof. In particular, the invention relates to three monoclonal antibodies, referred to as B1, B3, and B5, which are useful in the treatment and diagnosis of many forms of cancer.

Abstract: Monoclonal antibodies that bind specifically to prostate carcinoma and do not bind substantially to normal prostate or benign prostatic hyperplasia, as well as hybridoma cell lines producing the monoclonal antibodies are disclosed. In one embodiment, a monoclonal antibody designated MAb PD41 is disclosed. A new antigen designated prostate mucin antigen is disclosed in isolated, substantially pure form. In addition, methods for using the hybridoma cell lines, the monoclonal antibody and/or the antigen for diagnosis, prophylaxis and/or treatment of prostate carcinoma are disclosed.

Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.

Abstract: The subject invention relates to a novel method for vectored delivery of physiologically-active chemical agents to a target organ, tissue or cell of interest and uses thereof. In particular, medical vectoring reagents which localize in a specific target organ, tissue or cell are conjugated with a drug or therapeutic agent using a linking agent, and the resulting conjugate is then introduced into the body. The chemical agent is thereby localized in the target organ, tissue or cell for effecting a therapeutic or physiological benefit or change therein.

Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.

Abstract: An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.

Abstract: Human monophenotypic cloned cell lines of megakaryocytic lineage are established in vitro through use of adherent stromal cells in long term human bone marrow culture. Long term bone marrow cultures are used for initial adaptation of the cells to culture conditions. Once adapted, cells of the human in vitro cell lines are weaned from the stromal layer until they proliferate in the complete absence of any feeder layer. Seed cells for establishment of human in vitro cell lines were derived from a human solid tumor designated as ATCC CRL 9139 xenograft. Cells of one cloned in vitro cell line designated as CHRF-288-11 exhibits a karyotype and markers characteristic of megakaryocytes and platelets. Cells of the CHRF-288-11 cell line express platelet peroxidate, platelet factor IV, platelet Ca.sup.++ -ATPase, gpIIbIIIa, factor VIII, and MY7, MY9 and HLA-Dr antigens. CHRF-288-11 cell line exhibits a constant karyotype (50, XY).

Abstract: Hybrid proteins containing repressor proteins and substituted receptor binding sites, amino acid and DNA sequences encoding the hybrid proteins are provided. Methods for preparing the hybrid proteins are also described.

Abstract: A stable transformed HEK 293 cell comprising a functional GABA.sub.A receptor that comprises a GABA.sub.A receptor .alpha. subunit, a GABA.sub.A receptor .beta. subunit and a GABA.sub.A receptor .gamma. subunit is disclosed.

Abstract: Antibody preparation purified using immobilized protein A and yet substantially free of protein A that may have solubilized during the purificaiton process. The antibodies include less than 15 ng protein A per mg of antibody, preferably less than 1 ng/mg. Low protein A content is obtained by first contacting the antibodies and solubilized protein A with an ion exchange resin under conditions to adsorb both. The antibodies and protein A are then sequentially eluted under conditions of increasing ionic strength.